How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cardiac Drug Stent Market
- By Stent Type: Bare Metal Stents (BMS), Drug-Eluting Stents (DES), Bioabsorbable Vascular Scaffolds (BVS), Covered Stents
- By Drug Coating Type: Sirolimus-Eluting Stents, Paclitaxel-Eluting Stents, Everolimus-Eluting Stents, Zotarolimus-Eluting Stents
- By Indication: Coronary Artery Disease (CAD), Peripheral Artery Disease (PAD), Carotid Artery Disease, Renal Artery Stenosis
- By End User: Hospitals, Cardiac Specialty Clinics, Ambulatory Surgical Centers
- By Material: Stainless Steel, Cobalt-Chromium Alloy, Platinum-Chromium Alloy, Polymer-Based
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Bare Metal Stents (BMS) leads By Stent Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 14 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 14 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Cardiac Drug Stent Market report
A complete, evidence-based study - 12 chapters and 121 sections covering market size, segmentation across 5 axes, regional analysis and 14 company profiles, forecast to 2033.
Segmentation covered
Stent Type 4
Drug Coating Type 4
Indication 4
End User 3
Material 4
Companies profiled
Abbott Laboratories
Boston Scientific Corporation
Medtronic plc
Terumo Corporation
BIOTRONIK SE & Co. KG
Cordis (a Cardinal Health company)
Sino Medical Sciences Technology Inc.
Lepu Medical Technology (Beijing) Co. Ltd.
MicroPort Scientific Corporation
B. Braun Melsungen AG
Shanghai MicroPort Medical (Group) Co. Ltd.
OrbusNeich Medical
+2 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
14 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →BIOTRONIK SE & Co. KG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cordis (a Cardinal Health company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Sino Medical Sciences Technology Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Lepu Medical Technology (Beijing) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MicroPort Scientific Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →B. Braun Melsungen AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Shanghai MicroPort Medical (Group) Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →OrbusNeich Medical
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Jotec GmbH
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Helsinn Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,839M by 2033 · 10.3% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Bare Metal Stents (BMS)50.1
- Drug-Eluting Stents (DES)15.7
- Bioabsorbable Vascular Scaffolds (BVS)14.6
- Covered Stents19.6
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,033M → $2,258M · 10.3%
Europe$719.6M → $1,507M · 9.7%
Asia Pacific$657.1M → $1,416M · 10.1%
Latin America$406.8M → $850.8M · 9.7%
Middle East and Africa$312.9M → $635.2M · 9.3%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.222026
10.242027
10.242028
10.262029
10.262030
10.282031
10.292032
10.312033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories15.1
- Boston Scientific Corporation17.0
- Medtronic plc5.9
- Terumo Corporation7.6
- BIOTRONIK SE & Co. KG13.7
- Cordis (a Cardinal Health company)12.7
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Stent Type19.9%
Drug Coating Type26.4%
Indication12.1%
End User27.5%
Material14.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.9
- Europe22.6
- Asia Pacific21.2
- Latin America12.8
- Middle East and Africa9.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 85 | 86 | 76 | 93 | 94 | 92 | 88 |
| Boston Scientific Corporation | 72 | 81 | 73 | 83 | 69 | 83 | 77 |
| Medtronic plc | 78 | 69 | 70 | 80 | 72 | 71 | 73 |
| Terumo Corporation | 60 | 66 | 63 | 67 | 76 | 68 | 67 |
| BIOTRONIK SE & Co. KG | 58 | 66 | 74 | 74 | 57 | 54 | 64 |
| Cordis (a Cardinal Health company) | 69 | 49 | 47 | 66 | 55 | 55 | 57 |
| Sino Medical Sciences Technology Inc. | 59 | 42 | 43 | 59 | 44 | 43 | 48 |
| Lepu Medical Technology (Beijing) Co. Ltd. | 39 | 54 | 52 | 57 | 48 | 60 | 52 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Boston Scientific Corporation
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Boston Scientific Corporation | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Medtronic plc | ✓ | ◐ | ◐ | ✓ | − | ◐ |
| Terumo Corporation | ◐ | ◐ | − | ◐ | ✓ | ✓ |
| BIOTRONIK SE & Co. KG | − | ◐ | ◐ | ◐ | − | ◐ |
| Cordis (a Cardinal Health company) | ◐ | − | − | ◐ | ◐ | − |
| Sino Medical Sciences Technology Inc. | ◐ | − | − | ◐ | ◐ | − |
| Lepu Medical Technology (Beijing) Co. Ltd. | − | − | − | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories88
2Boston Scientific Corporation77
3Medtronic plc73
4Terumo Corporation67
5BIOTRONIK SE & Co. KG64
6Cordis (a Cardinal Health company)57
7Lepu Medical Technology (Beijing) Co. Ltd.52
8Sino Medical Sciences Technology Inc.48
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Abbott Laboratories
Challenger3
Strong scale, closing on the leaders.
Boston Scientific CorporationMedtronic plcTerumo Corporation
Contender2
Focused players with pockets of strength.
BIOTRONIK SE & Co. KGCordis (a Cardinal Health company)
Niche2
Specialists in a single segment or region.
Sino Medical Sciences Technology Inc.Lepu Medical Technology (Beijing) Co. Ltd.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Stent Type in North America, then scale across Cardiac Drug Stent Market — a $31M beachhead inside a $587M market.
Beachhead (SOM)$31Mobtainable near-term
Serviceable (SAM)$206Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Bare Metal Stents (BMS)
Best fit — highest urgency & budget in Stent Type.
Economic buyer75 fit
Drug-Eluting Stents (DES)
Strong fit — clear ROI and a fast path to value.
End user69 fit
Bioabsorbable Vascular Scaffolds (BVS)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Stent Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Coating Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel29%
Digital / self-serve23%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Stent Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cardiac Drug Stent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified22%
Evaluation12%
Closed-won6%
$17.9KCAC
$65KLTV
3.7:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cardiac Drug Stent Market is a resilient opportunity — $1.49B by 2033, compounding at 5.7%.
TAM · 2025$951Mtoday
TAM · 2033$1.49Bforecast
CAGR5.7%2027–2033
Cumulative$10.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.49BTotal addressable market
SAM$546MServiceable available market
SOM$95MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.7% CAGR
Demand compounds through 2033, outpacing GDP across Stent Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Stent Type moving from early to mainstream — durable secular demand.
Consolidation upside
14+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.49BLarge & growingTAM by 2033 at 5.7% CAGR
$546MServiceable nowreachable with today’s model
$95MBeachhead winobtainable near-term share
14+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.16BBear3.7% CAGR
$1.49BBase5.7% CAGR
$1.90BBull7.6% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Coating Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cardiac Drug Stent Market — a $3.83B market by 2033. Plan: grow share from 10.1% to 17.0%.
Market size · 2033$3.83Btotal addressable
Market CAGR5.5%2027–2033
Target share17.0%from 10.1% today
Revenue ambition$651Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.1% | 17.0% | At risk |
| Revenue | $389M | $651M | At risk |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.2% | 43.3% | On track |
| Customer retention | 90.8% | 96.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Stent Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Coating Type capability
A defensible second engine — invest in Drug Coating Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Stent Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Coating Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $84M capacity & capability investment
- Greenlight bolt-on M&A in Drug Coating Type
- Authorise North America expansion plan
- Fund R&D program for Stent Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossOn track
- Input-cost & supply riskAhead
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cardiac Drug Stent Market conversation — a $2.23B market you can size, segment and defend in minutes.
Market size · 2033$2.23Btotal opportunity
Growth5.4%CAGR to 2033
Addressable buyers1,367+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Stent Type
Goal Grow share in Stent Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 4 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
14+players profiled in this market
Coverage includes
Abbott LaboratoriesBoston Scientific CorporationMedtronic plcTerumo CorporationBIOTRONIK SE & Co. KGCordis (a Cardinal Health company)Sino Medical Sciences Technology Inc.Lepu Medical Technology (Beijing) Co. Ltd.+6 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cardiac Drug Stent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cardiac Drug Stent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cardiac Echocardiography Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportCardiac Electric Pacing Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportCardiac Electrophysiology Ddiagnostic Catheter Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCardiac Equipments Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportCardiac Event Ambulatory Monitors Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportCardiac Event Monitor Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCardiac Fibrosis Drug Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportCardiac Holter Monitors Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportCardiac Marker Analyzers Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCardiac Markers Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCardiac Medical Device Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportCardiac Monitor Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.